GO:0043331 response to dsRNA: Innate Immune Sensing Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043331 (response to dsRNA) describes any cellular or organismal change triggered by double-stranded RNA, a key danger signal in antiviral immunity and cancer.
• Endogenous dsRNA arises from retroelements, mitochondrial transcripts, and long 3'UTRs, and is normally suppressed by RNA editing and degradation pathways.
• MDA5 (IFIH1) and other sensors recognize dsRNA to initiate interferon signaling, and loss of self-tolerance to Alu duplex RNA causes MDA5-mediated inflammation.
• ADAR1 editing masks dsRNA and prevents ZBP1-driven necroptosis, limiting the immunotherapeutic promise of ZBP1 activation in cancer.
• DHX9 loss triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer, linking dsRNA response to therapeutic vulnerability.
• Oncogenic KRAS impairs DDX60-mediated dsRNA accumulation and viral mimicry, driving immunosuppression in colorectal cancer.
Description
The Gene Ontology term GO:0043331, response to dsRNA, defines any process that results in a change in state or activity of a cell or an organism as a result of a double-stranded RNA stimulus. This biological process is central to innate immunity, as dsRNA is a hallmark of viral infection and also arises from endogenous sources such as retroelements and mitochondrial transcripts. Researchers study this term to understand how cells distinguish self from non-self RNA and how dysregulation contributes to autoinflammation and cancer. The response to dsRNA encompasses sensing, signaling, and downstream effector programs including interferon production, necroptosis, and translational arrest. Because dsRNA can be generated from Alu elements and long 3'UTRs, this pathway is also implicated in neuronal inflammation and neurodegenerative conditions. In cancer, endogenous dsRNA and viral mimicry responses influence immunotherapy outcomes and tumor cell vulnerability. This article synthesizes authoritative GO annotations and verified literature to provide a research-grade overview of GO:0043331, its genes, mechanisms, and experimental models.
response to dsRNA At A Glance
| GO ID | GO:0043331 |
|---|---|
| GO term | response to dsRNA |
| Ontology | biological_process |
| Synonym | response to double-stranded RNA |
| Definition | Any process that results in a change in state or activity of a cell or an organism as a result of a double-stranded RNA stimulus. |
| Major function | Innate immune sensing of dsRNA leading to interferon signaling, necroptosis, and translational control. |
| Key sensors | MDA5 (IFIH1), RIG-I (DDX58), PKR (EIF2AK2), ZBP1, and DHX9. |
| Endogenous sources | Retroelements, mitochondrial dsRNA, and long 3'UTRs. |
| Related diseases | Autoinflammation, cancer, and neurodegeneration. |
What Is GO:0043331?
In our own words, response to dsRNA (GO:0043331) is the collection of cellular and organismal changes triggered when double-stranded RNA is detected. These changes can include altered gene expression, secretion of cytokines, enzyme production, and even cell death, all initiated by dsRNA as a stimulus. The term covers the full arc from initial sensing to downstream physiological outcomes, and it is distinct from the mere presence of dsRNA because it requires a measurable response.
Why Is response to dsRNA Important in Cell Biology?
Understanding response to dsRNA is critical because this pathway sits at the intersection of antiviral defense, autoimmunity, and cancer immunotherapy. Dysregulated dsRNA sensing can cause severe inflammatory diseases, while tumors often exploit dsRNA pathways to evade immune detection. Moreover, therapeutic strategies that induce viral mimicry or target dsRNA-handling enzymes are emerging as promising anticancer approaches.
• dsRNA is a universal viral signature and a trigger of type I interferon responses.
• Endogenous dsRNA from Alu elements can breach self-tolerance and cause MDA5-mediated inflammation.
• ADAR1 editing of dsRNA prevents ZBP1-driven necroptosis, affecting cancer immunotherapy.
• Long 3'UTRs in neurons promote immunostimulatory dsRNA formation, linking to neurodegeneration.
• Oncogenic KRAS impairs DDX60-mediated dsRNA accumulation, contributing to immunosuppression in colorectal cancer.
• DHX9 targeting induces interferon response and replication stress in small cell lung cancer.
• Mitochondrial dsRNA modification by 5-methylcytosine controls its degradation and cytosolic release.
• Retroelements and viral mimicry responses influence cancer therapy and cellular homeostasis.
• The pathway is a source of biomarkers and therapeutic targets for inflammatory and malignant diseases.
What Happens During response to dsRNA?
dsRNA sensing by innate immune receptors
In simple terms: Cells have sentinels that grab double-stranded RNA and sound an alarm.
The response begins when cytosolic sensors such as MDA5 (IFIH1) and RIG-I (DDX58) bind dsRNA. MDA5 recognizes long dsRNA structures, including Alu duplexes, and triggers interferon signaling. This sensing is a key step in antiviral immunity and is also activated by endogenous dsRNA from retroelements.
Signal amplification and interferon induction
In simple terms: The alarm spreads, causing the cell to produce antiviral and inflammatory molecules.
Upon dsRNA recognition, signaling cascades activate transcription factors that induce type I interferons and interferon-stimulated genes. This amplification loop is essential for restricting viral spread and is co-opted in cancer viral mimicry responses. DHX9 loss can trigger a tumor-intrinsic interferon response, demonstrating the pathway's therapeutic potential.
Downstream effector programs: necroptosis and translational arrest
In simple terms: The cell can choose to die or stop making proteins to block infection.
dsRNA sensing can activate ZBP1-dependent necroptosis, a form of programmed cell death. ADAR1 editing masks dsRNA and prevents ZBP1-driven necroptosis, thereby limiting immunotherapy efficacy. Additionally, PKR (EIF2AK2) phosphorylates eIF2alpha to halt translation, a classic antiviral response.
Endogenous dsRNA sources and their regulation
In simple terms: dsRNA can come from within our own cells, not just viruses.
Endogenous dsRNA arises from retroelements, mitochondrial transcripts, and long 3'UTRs. Mitochondrial dsRNA is marked by 5-methylcytosine for degradation and cytosolic release. Long 3'UTRs predispose neurons to inflammation by promoting immunostimulatory dsRNA formation. These sources are normally kept in check by RNA editing and degradation enzymes.
Key Genes Involved in GO:0043331 response to dsRNA
The following genes and proteins are central to the response to dsRNA, based on verified literature and GO annotations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFIH1 (MDA5) | Cytosolic dsRNA sensor | Mediates inflammation to Alu duplex RNA |
| DDX58 (RIG-I) | Cytosolic dsRNA sensor | Antiviral signaling and interferon induction |
| EIF2AK2 (PKR) | dsRNA-activated kinase | Translational arrest and antiviral defense |
| ZBP1 | dsRNA sensor for necroptosis | Drives necroptosis masked by ADAR1 |
| ADAR1 | RNA editing enzyme | Masks dsRNA to prevent autoinflammation |
| DHX9 | RNA helicase | Loss triggers interferon response in SCLC |
| DDX60 | dsRNA accumulation factor | KRAS impairs its function in colorectal cancer |
| KRAS | Oncogene | Drives immunosuppression via DDX60 |
| MDA5 | See IFIH1 | Same as IFIH1 |
| RIG-I | See DDX58 | Same as DDX58 |
| PKR | See EIF2AK2 | Same as EIF2AK2 |
| ZBP1 | Z-DNA binding protein 1 | Necroptosis induction |
| ADAR1 | Adenosine deaminase | RNA editing |
| DHX9 | DExH-box helicase | Interferon response |
| DDX60 | DEAD-box helicase | dsRNA accumulation |
| KRAS | GTPase | Oncogenic signaling |
| Mitochondrial dsRNA | Endogenous dsRNA source | Regulated by 5-methylcytosine |
How Is response to dsRNA Regulated?
The response to dsRNA is tightly regulated at multiple levels. RNA editing by ADAR1 converts adenosine to inosine in dsRNA, preventing MDA5 and ZBP1 activation and maintaining self-tolerance. Mitochondrial dsRNA is marked by 5-methylcytosine, which targets it for degradation and limits cytosolic release. Oncogenic KRAS can impair DDX60-mediated dsRNA accumulation, thereby dampening viral mimicry and immune detection in colorectal cancer. Additionally, long 3'UTRs can promote immunostimulatory dsRNA formation in neurons, suggesting that 3'UTR processing is a regulatory node. These mechanisms ensure that dsRNA responses are potent against pathogens but restrained against self-RNA.
response to dsRNA and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DHX9 | Small cell lung cancer | Knockout in SCLC cell lines |
| ADAR1 | Cancer immunotherapy resistance | Point mutation or knockout in melanoma models |
| KRAS | Colorectal cancer immunosuppression | Knock-in of mutant KRAS in colorectal cells |
| IFIH1 (MDA5) | Autoinflammation | Knock-in of gain-of-function variants |
| Mitochondrial dsRNA | Inflammatory release | Overexpression of m5C writers |
Cancer and viral mimicry
In cancer, endogenous dsRNA can trigger viral mimicry responses that make tumors more immunogenic. DHX9 targeting in small cell lung cancer induces tumor-intrinsic interferon response and replication stress, highlighting a therapeutic strategy. Oncogenic KRAS impairs DDX60-mediated dsRNA accumulation, leading to immunosuppression in colorectal cancer. ADAR1 masks dsRNA and limits the cancer immunotherapeutic promise of ZBP1-driven necroptosis. These findings link dsRNA response to immunotherapy outcomes and tumor cell vulnerability.
Autoinflammation and self-tolerance
Breaching self-tolerance to Alu duplex RNA underlies MDA5-mediated inflammation, a mechanism relevant to autoimmune and autoinflammatory diseases. Loss of ADAR1 function can lead to uncontrolled dsRNA sensing and ZBP1-dependent necroptosis, causing severe inflammatory pathology. These examples illustrate how defects in dsRNA regulation cause human disease.
Neurodegeneration and neuronal inflammation
Long 3'UTRs predispose neurons to inflammation by promoting immunostimulatory dsRNA formation. This suggests that neuronal cells are particularly vulnerable to dsRNA-driven inflammation, which may contribute to neurodegenerative conditions. Mitochondrial dsRNA release, regulated by 5-methylcytosine, can also activate cytosolic dsRNA sensors and exacerbate inflammation.
From response to dsRNA-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DHX9 induce interferon response? | DHX9 knockout in SCLC cell lines |
| Can ADAR1 editing prevent ZBP1 necroptosis? | ADAR1 point mutation or knockout |
| How does KRAS affect DDX60-mediated dsRNA accumulation? | KRAS mutant knock-in in colorectal cells |
| Do Alu duplexes trigger MDA5 inflammation? | MDA5 overexpression or knock-in |
| Is mitochondrial dsRNA release regulated by m5C? | Knockout of m5C writers or readers |
| Do long 3'UTRs promote dsRNA formation? | 3'UTR knock-in or overexpression |
How to Study the response to dsRNA Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes and retroelement expression | Identify endogenous dsRNA sources |
| dsRNA immunoprecipitation | dsRNA abundance and localization | Detect Alu duplexes |
| ISRE reporter assay | Interferon pathway activation | Test gene knockouts |
| Phospho-MLKL immunoblot | Necroptosis activation | Study ZBP1-driven death |
| Mass spectrometry | Protein interactions and modifications | Map dsRNA sensor complexes |
| CRISPR knockout screens | Gene essentiality in dsRNA response | Discover regulators |
| Mitochondrial dsRNA isolation | Mitochondrial dsRNA release | Study m5C regulation |
RNA sequencing and dsRNA detection
RNA-seq can identify endogenous dsRNA sources such as retroelements and long 3'UTRs. Specialized protocols like J2 antibody immunoprecipitation or dsRNA-specific sequencing can enrich for dsRNA. These methods help quantify dsRNA accumulation upon genetic perturbations.
Interferon reporter assays
Luciferase or GFP reporters driven by interferon-stimulated response elements (ISRE) measure pathway activation. Such assays are used to test whether genes like DHX9 or ADAR1 regulate dsRNA sensing.
Cell death and necroptosis assays
ZBP1-driven necroptosis can be measured by viability assays, phospho-MLKL immunoblotting, and caspase inhibition. These methods are essential to study ADAR1 masking of dsRNA.
Proteomics and immunoprecipitation
Mass spectrometry and co-immunoprecipitation identify dsRNA sensor complexes and post-translational modifications. These approaches reveal how DDX60 or DHX9 interact with dsRNA and signaling partners.
How CRISPR Can Be Used to Study GO:0043331 response to dsRNA
Knockout
CRISPR knockout of genes such as DHX9, ADAR1, or DDX60 allows researchers to test their role in dsRNA response. For example, DHX9 knockout induces interferon response in small cell lung cancer. ADAR1 knockout unmasks ZBP1-driven necroptosis.
Point Mutation
Point mutations can mimic disease-associated variants or catalytic dead versions. For instance, editing active-site residues of ADAR1 or MDA5 can dissect editing-dependent versus sensing functions.
Knock-in
Knock-in of mutant KRAS or gain-of-function MDA5 variants models cancer and autoinflammation. These models help study how oncogenic signaling impairs dsRNA accumulation.
Overexpression
Overexpression of dsRNA sensors or editing enzymes can amplify or suppress the response. Overexpressing ADAR1 masks dsRNA, while overexpressing MDA5 enhances inflammation.
How EDITGENE Supports response to dsRNA Research
Researchers studying response to dsRNA-related genes often need to determine whether a candidate gene is causally involved in dsRNA sensing, editing, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR services to create precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for response to dsRNA research.
Frequently Asked Questions About response to dsRNA
What is GO:0043331 response to dsRNA?
GO:0043331 is a Gene Ontology biological process term describing any cellular or organismal change triggered by double-stranded RNA, including interferon signaling and cell death.
What genes are involved in response to dsRNA?
Key genes include IFIH1 (MDA5), DDX58 (RIG-I), EIF2AK2 (PKR), ZBP1, ADAR1, DHX9, and DDX60.
How does dsRNA trigger innate immunity?
dsRNA is sensed by cytosolic receptors like MDA5 and RIG-I, which activate interferon signaling and antiviral programs.
What diseases are linked to dsRNA response?
Diseases include autoinflammation, cancer, and neurodegeneration, with examples like MDA5-mediated inflammation and ADAR1-related immunotherapy resistance.
What is the role of ADAR1 in dsRNA response?
ADAR1 edits dsRNA to prevent sensing by MDA5 and ZBP1, thereby limiting autoinflammation and necroptosis.
How is mitochondrial dsRNA regulated?
Mitochondrial dsRNA is marked by 5-methylcytosine for degradation and controlled cytosolic release.
Can CRISPR be used to study response to dsRNA?
Yes, CRISPR knockout, knock-in, and point mutation models are widely used to dissect dsRNA pathway genes.
What is viral mimicry in cancer?
Viral mimicry is the activation of antiviral dsRNA responses in tumors, which can enhance immunotherapy efficacy.
How does KRAS affect dsRNA accumulation?
Oncogenic KRAS impairs DDX60-mediated dsRNA accumulation, leading to immunosuppression in colorectal cancer.
What experimental models are used for dsRNA research?
Common models include knockout cell lines, reporter assays, and RNA-seq, as well as CRISPR screens.
Conclusion
GO:0043331 response to dsRNA is a fundamental biological process that bridges antiviral immunity, autoinflammation, and cancer. The interplay between dsRNA sources, sensors, and editing enzymes determines whether cells mount a protective or pathological response. Continued research using CRISPR models and advanced sequencing will uncover new therapeutic opportunities targeting this pathway.
References
- 1. Murayama T et al.. 2024. Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer.. Cancer Discov 14(3):468-491 PMID: 38189443
- 2. Zhang T et al.. 2022. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis.. Nature 606(7914):594-602 PMID: 35614224
- 3. Chen YG et al.. 2022. Cellular origins of dsRNA, their recognition and consequences.. Nat Rev Mol Cell Biol 23(4):286-301 PMID: 34815573
- 4. Zhou Y et al.. 2024. Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry.. Sci Immunol 9(100):eado8758 PMID: 39365875
- 5. Ahmad S et al.. 2018. Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation.. Cell 172(4):797-810.e13 PMID: 29395326
- 6. Dorrity TJ et al.. 2023. Long 3'UTRs predispose neurons to inflammation by promoting immunostimulatory double-stranded RNA formation.. Sci Immunol 8(88):eadg2979 PMID: 37862432
- 7. Chen R et al.. 2021. Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis.. Cancer Discov 11(11):2707-2725 PMID: 34649957
- 8. Kim S et al.. 2024. RNA 5-methylcytosine marks mitochondrial double-stranded RNAs for degradation and cytosolic release.. Mol Cell 84(15):2935-2948.e7 PMID: 39019044
